Sprycel News and Research

RSS
On June 28, 2006, the FDA granted accelerated approval of SPRYCEL for the treatment of adults in all three phases of CML (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec. The FDA also granted full approval of SPRYCEL for the treatment of adults with Ph+ ALL with resistance or intolerance to prior therapy. SPRYCEL is the first approved oral tyrosine kinase inhibitor that, at nanomolar concentrations, inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß kinases. The active ingredient of SPRYCEL is dasatinib. Dasatinib reduces the activity of one or more proteins responsible for the uncontrolled growth of the leukemia cells of patients with CML or Ph+ ALL.
MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

CAS researchers confirm Gleevec’s first generation drug targets chronic myelogenous leukemia

CAS researchers confirm Gleevec’s first generation drug targets chronic myelogenous leukemia

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta second-quarter net loss increases to $9.1 million

Synta second-quarter net loss increases to $9.1 million

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA approves new indication for Tasigna in treatment of rare blood cancer

FDA approves new indication for Tasigna in treatment of rare blood cancer

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010